$3.99
Today
as of Jul 22, 16:25 ET
Last 30 days
Recent Press Releases & News
Akari Therapeutics, Whitehawk Therapeutics Collaborate to Develop ADC Cancer Treatments
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
Overview
52-week range
$1.57
$5.50
62% of range
Avg surprise (last 3)
-74.1%
Avg reaction (last 2)
-2.2%
50% positive
Latest IV / EM
98%
EM ±19.1% · $5 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.32 | $-0.36 | +11.1% | +11.1% | -5.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.26 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.76 | $0.49 | -255.1% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.36 | $-0.46 | +21.7% | — | +0.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.46 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.54 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.68 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.60 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.67 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.30 | -$0.76 | +60.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 | $7M | — | $7M | $6M |
| Cost of revenue | $0 | — | $0 | $0 | $760,000 | — | $804,000 | $778,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-24M | — | $-20M | $-55M | $-15M | — | $-13M | $-16M |
| Net income | $-22M | — | $-18M | $-53M | $73M | — | $-13M | $-15M |
| EPS (diluted) | $-0.32 | — | $-0.26 | $-0.76 | $1.83 | — | $-0.46 | $-0.54 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $35M | $38M | $38M | $145M | $228M | $29M | $31M | $41M |
| Inventory | — | — | $0 | $0 | $0 | $5M | $5M | $6M |
| Total current assets | $126M | $149M | $165M | $179M | $233M | $61M | $77M | $93M |
| Total assets | $127M | $151M | $167M | $181M | $234M | $70M | $86M | $102M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $15M | $10M | $9M | $12M | $18M | $17M | $23M |
| Total equity | $116M | $136M | $157M | $172M | $222M | $52M | $69M | $79M |